Lactobacillus paragasseri BDUP2 for relieving eczema-like discomfort and application of lactobacillus paragasseri BDUP2

Abstract

The invention belongs to the technical field of microorganisms, and discloses an application of lactobacillus paragasseri BDUP2 in preparation of products for preventing or improving the skin barrier function or improving eczema-like discomfort and skin inflammation, and the preservation number of the strain BDUP2 is CGMCC No.35759. The invention further discloses a preparation method of the lactobacillus paragasseri BDUP2. Research results show that the lactobacillus gasseri BDUP2 strain can regulate the inflammatory factor level on the cellular level; in an eczema mouse model, BDUP2 is helpful to alleviate skin erythema, swelling, dryness, scabbing, pruritus and other discomfort performances, reduce transdermal moisture loss and promote maintenance of skin barrier functions. The strain can also regulate the level of pruritus-related factors, enhance the antioxidant capacity of skin and support skin health. The BDUP2 strain can be used for preparing various products for relieving eczema, provides a new safe and effective way for improving eczema, and has wide application prospect and market value.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of microbiology, in particular to the use of Lactobacillus paragasseri strain BDUP2 in the preparation of products for relieving eczema. BACKGROUND

[0002] Eczema is a chronic inflammatory skin disease with high incidence, great harm and difficult intervention. Patients often have symptoms such as skin itching, erythema, exudation, etc., which not only affect appearance, but also cause sleep disorders and increase psychological stress due to long-term discomfort, greatly reducing the quality of life. At present, the pathogenesis of eczema is not fully understood, and multiple factors such as genetic factors, immune abnormalities, environmental stimuli and skin microbial flora imbalance interact to jointly promote the occurrence and development of the disease.

[0003] In terms of intervention, traditional glucocorticoids and immunosuppressants can quickly relieve symptoms, but long-term use can cause skin atrophy, telangiectasia, increased risk of infection and other serious side effects, and the disease is prone to relapse after drug withdrawal. Emerging phototherapy and biological agents have certain improvement effects, but they have problems such as high cost, high equipment requirements, and inapplicability to some patients, making it difficult to meet the intervention needs of the majority of patients with eczema. Therefore, it is urgent to find safe, effective and widely applicable new means (such as food and cosmetics) for preventing and relieving eczema.

[0004] In recent years, more and more research has focused on the correlation between intestinal flora and skin diseases. Intestinal flora is an important microecosystem of the human body, and the balance of its composition and function is crucial to maintaining the health of the body. Analysis by 16S rRNA sequencing and other techniques has found that the number of beneficial bacteria such as Bifidobacterium and Lactobacillus in the intestines of eczema patients is significantly reduced, while the proportion of opportunistic pathogens such as Enterobacter and Staphylococcus is significantly increased. This imbalance of the flora affects the function of the intestinal mucosal barrier, increases intestinal permeability, and causes antigens, endotoxins and other substances in the intestines to translocate into the blood circulation, activate the immune system, trigger systemic inflammatory response, and further aggravate skin inflammatory lesions through the "gut-skin axis".

[0005] Lactobacillus paragasseri is a potential probiotic that has shown great potential in the prevention and improvement of inflammatory diseases such as colitis, asthma and food allergies, but relevant research in the field of eczema prevention and improvement is still in its infancy. It is not yet clear what the specific target and molecular mechanism of Lactobacillus paragasseri are for relieving eczema. Therefore, it is of great health significance and broad market prospects to explore efficient, safe and beneficial Lactobacillus paragasseri and develop innovative products for eczema prevention and improvement based on it. SUMMARY

[0006] To solve the above technical problems, the present application provides a Lactobacillus paragasseri BDUP2, the preservation number of which is CGMCC No. 35759.

[0007] Another aspect of the present application provides use of the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2 in the preparation of a product for improving skin health or supporting skin barrier function. Preferably, the product is used for improving skin health or supporting skin barrier function, including relieving skin redness, dryness, desquamation, reducing transepidermal water loss.

[0008] Another aspect of the present application provides use of the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2 in the preparation of a product for relieving eczema-like discomfort. Preferably, the product is used for relieving conditions associated with eczema-like discomfort including skin swelling, redness, dryness, desquamation, crusting, itching, inflammatory response or skin oxidative damage.

[0009] Another aspect of the present application provides use of the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2 in the preparation of a product for modulating the level of pruritogens or pruritogenic peptides.

[0010] Another aspect of the present application provides use of the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2 in the preparation of a product for relieving skin oxidative damage, or enhancing skin antioxidant defense capacity.

[0011] Another aspect of the present application provides a product comprising an effective amount of the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2. Preferably, the product is a food, health product or cosmetic product.

[0012] Another aspect of the present application provides a product preparation method, the method comprising: adding the live, dead, metabolite, supernatant, bacterial agent or composition of Lactobacillus paragasseri BDUP2 to a product matrix to obtain the product.

[0013] The Lactobacillus paragasseri BDUP2 can effectively improve the skin barrier function, relieve the itching behavior and the eczema-like inflammatory response in the DNCB-induced mouse eczema model, and the working mechanism is related to inhibiting the Th2-type immune response, supporting the immune balance, and regulating the itching perception neural pathway, regulating the itching factor and the neuropeptide. The above-mentioned effects show that the Lactobacillus paragasseri BDUP2 has application value in food, health products or cosmetics, and can be used for developing products for improving the skin state, relieving the eczema-like discomfort and supporting the skin health, thereby providing a new safe and effective skin management option for consumers.

[0014] The strain preservation of the present application is as follows:

[0015] Strain name: BDUP2

[0016] Latin name: Lactobacillus paragasseri

[0017] Classification name: Lactobacillus paragasseri

[0018] Strain number: 35759

[0019] Preservation agency: China General Microbiological Culture Collection Center

[0020] Abbreviation of the preservation agency: CGMCC

[0021] Address: No. 3, Beichen West Road, Beijing City, China

[0022] Preservation date: August 28, 2025

[0023] Preservation center registration number: CGMCC No. 35759 BRIEF DESCRIPTION OF DRAWINGS

[0024] In order to more clearly illustrate the specific embodiments of the present application or the technical solutions in the prior art, the drawings needed in the specific embodiments or the prior art description will be briefly introduced below. Obviously, the drawings in the following description are some embodiments of the present application, and those skilled in the art can also obtain other drawings according to these drawings without creative labor.

[0025] Figure 1 TNF-α (A), IFN-γ (B), IL-1β (C), IL-6 (D) and IL-10 (E) levels of HaCaT cells treated by the Lactobacillus paragasseri BDUP2 of the present application. n=6, *p<0.05, **p<0.01, ***p<0.001.

[0026] Figure 2 Serum levels of specific antibodies IgE (A) and IgG1 (B) in mice with eczema model after receiving Lactobacillus paragasseri BDUP2 treatment. n = 8, *p < 0.05, **p < 0.01, ***p < 0.001.

[0027] Figure 3 Serum levels of inflammation-related cytokines IL-4 (A), IL-13 (B), IL-31 (C), TNF-α (D), IFN-γ (E), and IL-10 (F) in mice with eczema model after receiving Lactobacillus paragasseri BDUP2 treatment. n = 8, *p < 0.05, **p < 0.01, ***p < 0.001.

[0028] Figure 4 Serum levels of itch-related neuropeptides Substance P (SP) (A), calcitonin gene-related peptide CGRP (B), and nerve growth factor NGF (C) in mice with eczema model after receiving Lactobacillus paragasseri BDUP2 treatment. n = 8, *p < 0.05, **p < 0.01, ***p < 0.001.

[0029] Figure 5 Oxidative stress-related indicators propylene glycol (MDA) (A) and superoxide dismutase (SOD) (B) in skin tissue of mice with eczema model after receiving Lactobacillus paragasseri BDUP2 treatment. n = 8, *p < 0.05, **p < 0.01, ***p < 0.001.

[0030] Figure 6 mRNA expression levels of itch factors Nppb (A), MrgprA3 (B), IL-31 (C), and TRPV1 (D) in skin tissue of mice with eczema model after receiving Lactobacillus paragasseri BDUP2 treatment. n = 8, *p < 0.05, **p < 0.01, ***p < 0.001. DETAILED DESCRIPTION

[0031] The content of the present application is further described in detail below through specific examples. The raw materials, reagents or devices used in the examples and comparative examples, unless otherwise specified, can be obtained from conventional commercial channels, or can be obtained by existing technical methods. Unless otherwise specified, the test or test method is a conventional method in the art.

[0032] Example 1. Evaluation of the effect of Lactobacillus paragasseri BDUP2 on improving the inflammatory response of HaCaT skin cells

[0033] (1) Experimental method

[0034] This example uses HaCaT human immortalized keratinocytes to perform the following experiments. Cells are cultured in DMEM medium (with 10% fetal bovine serum) and the culture environment is 5% CO2 and 37°C. Logarithmic growth phase HaCaT cells are seeded into a 96-well plate (5x10 3 The cells are cultured for 22-24 h, and then grouped and treated according to experimental requirements: a blank group (NC) (normal culture conditions), a model group (MC) (25 μg / L of TNF-α is added), a BDUP2 group (25 μg / L of TNF-α + 10% of the strain culture supernatant), and a positive control dexamethasone (Dex) group (25 μg / L of TNF-α + 1 μM of Dex) are cultured for 24 h.

[0035] After the strain-treated cells, the culture supernatant of each group is aspirated and collected, and the levels of TNF-α, IFN-γ, IL-1β, IL-6, and IL-10 are detected using the corresponding inflammatory factor ELISA kit. The specific steps are described in the kit instructions.

[0036] (2) Experimental results

[0037] Compared with the blank group (NC) Figure 1 ), the contents of pro-inflammatory factors TNF-α, IFN-γ, IL-1β, and IL-6 in the culture supernatant of the HaCaT cells of the model MC group were significantly increased, and the level of the anti-inflammatory factor IL-10 was also decreased, indicating that the skin inflammation state appeared; compared with the MC group, Dex treatment can reduce the high TNF-α, IFN-γ, IL-6, and IL-1β contents caused by eczema; and can also increase the IL-10 level.

[0038] In the experimental group treated with Lactobacillus gasseri BDU2P, compared with the MC group, the contents of TNF-α, IFN-γ, IL-1β, and IL-6 were reduced, and the content of IL-10 was also increased. The regulatory effect of BDUP2 on these inflammatory factors is close to that of Dex. The above results show that the Lactobacillus gasseri BDUP2 strain described in the present application can reduce the content of pro-inflammatory factors and increase the level of anti-inflammatory factors at the cellular level, thereby exerting the effect of improving skin inflammation.

[0039] Example 2. Evaluation of the effect of Lactobacillus gasseri BDUP2 on improving the condition of eczema model mice

[0040] (1) Experimental method

[0041] ① Establishment of an eczema mouse model

[0042] Forty 6-week-old SPF BALB / c male mice (8 per group) were randomly divided into: a blank group (NC), a model group (MC), a BDUP2 live bacterial solution group (BDUP2), a BDUP2 inactivated bacterial solution group (p-BDUP2), and a positive control 0.1% dexamethasone group, according to body weight after 7 days of laboratory adaptation. Each bacterial solution group first received a week of feed containing Lactobacillus paracasei (15 mL of Lactobacillus paracasei bacterial solution mixed with 40 g of feed), twice a day, to allow the bacteria to colonize the intestinal tract of the mice. The remaining blank and model groups were fed with an equal amount of normal saline. Then, the model and probiotic groups of mice were shaved with a razor and hair remover, and 2,4-dinitrochlorobenzene group (DNCB, 2%) 50 μL was used to induce skin sensitization for 3 consecutive days. After 2 days, the mice were again treated with DNCB (1%) 50 μL for 3 days. Then, the bacterial solution groups of mice were again fed with feed containing Lactobacillus paracasei, and the mice were allowed to eat freely for 10 days.

[0043] ② Detection index

[0044] Each mouse was recorded for 60 minutes per week, and the scratching behavior was recorded to calculate the scratching duration. The Tewameter™300 instrument (TM300-MDD, Germany) was used to measure the trans-epidermal water loss (TEWL) to reflect the skin barrier function status. The mouse back skin was scored for redness / hemorrhage, edema / swelling, dryness / desquamation, scabbing / scarring, each with 0-3 points, and the total score was 12 points.

[0045] After the experiment, the right ear thickness of each group of mice was measured with a vernier caliper. After the mice were sacrificed, the ear tissue sample was taken out with a 6 mm puncher and weighed. The ear swelling degree was calculated as follows: Swelling degree = right ear piece thickness - left ear piece thickness.

[0046] The body weight, thymus and spleen weights of the mice in each group were measured, and the thymus index and spleen index were calculated, respectively. Thymus index = thymus weight / mouse body weight, spleen index = spleen weight / mouse body weight.

[0047] Orbital blood was collected from each group of mice, and the blood was centrifuged at 3000 r / min for 10 min after standing at room temperature for 30 min to obtain serum, which was collected and transferred into a centrifuge tube and stored at -20°C for use. The levels of immunoglobulin IgE and IgG1, inflammation-related factors IL-4, IL-13, IL-31, TNF-α, IFN-γ and IL-10, and the levels of itching-related neuropeptides SP, CGRP and NGF in the serum of the mice were detected using the corresponding ELISA kit.

[0048] The skin tissues of the mice in each group were taken, homogenized in an ice bath with a tissue homogenizer, and then the contents of the oxidative stress indicators MDA and SOD in the skin tissues were detected using an ELISA kit. In addition, total RNA was extracted using Trizol reagent. Qualified total RNA was reverse transcribed into cDNA using a reverse transcription kit. RT-qPCR was performed using the SYBR Green dye method on a real-time fluorescence quantitative PCR instrument. The relative expression of the skin itching factors Nppb, MrgprA3, IL-31 and TRPV1 was calculated using the relative quantification method.

[0049] (2) Experimental results

[0050] ① BDUP2 strain relieves the skin condition and itching behavior of the eczema model mice

[0051] After the experiment, it was found that the model mice had obvious swelling, erythema, edema, and papules on their ears, indicating that the modeling was successful. The skin inflammation degree of the mice in each group was evaluated using the skin lesion scoring method, and the score range was 0-12 points. The total score: 0-3 was mild, 4-7 was moderate, and 8-12 was severe eczema. According to Table 1, the score of the blank group mice was 0.6±0.3, the average score of the model group was 8.9±0.7, the Dex group was 2.9±0.4, and the average score of the live bacteria intervention group BDUP2 group was 3.4±0.5, which was significantly lower than that of the model group. The average score of the inactivated bacteria group was 4.6±0.2, which was slightly lower than that of the live bacteria group, indicating that the live state of the BDUP2 strain could effectively relieve the redness, swelling and dryness and scaling symptoms of skin eczema.

[0052] In terms of scratching behavior, the average time of the model group mice scratching the skin increased from 12s of the blank group to 119s (experimental results as shown in Table 1); while the live bacteria intervention group BDUP2 group of mice had a scratching time of 33s, and its relief effect was slightly lower than that of the Dex group (25s). The BDUP2 inactivated bacteria group also relieved the itching of the mice, but the effect was slightly worse than that of the live bacteria liquid group, and the corresponding scratching time was reduced to 56s.

[0053] In addition, the value of transepidermal water loss (TEWL) of the back skin showed that compared with the blank group, the TEWL of the model group was significantly increased (4.3±2.6 g / m² / h VS. 40.2±4.5 g / m² / h), while the live bacteria intervention group BDUP2 group was significantly decreased to 18.4±1.9 g / m² / h, close to the level of the Dex group (15.8±3.1 g / m² / h), and the inactivated bacteria group also reduced the TEWL after intervention, with a value of 22.9±2.7 g / m² / h. The increase of TEWL indicates that the skin barrier function is damaged, and the higher the value, the more serious the damage. These results suggest that the BDUP2 strain of the present application, including live bacteria and dead bacteria, can significantly improve the skin barrier function.

[0054] Table 1. Skin pathology, scratching behavior and TEWL evaluation of eczema mice

[0055] Group Lesion score Scratch time (s) Scratch times TEWL score (g / m2 / h) Blank group 0.6±0.3 12±1.09 9±0.55 4.3±2.6 Model group 8.9±0.7 119±3.21 76±2.59 40.2±4.5 Dex group 2.9±0.4（***） 25±3.84（***） 17±0.31（***） 15.8±3.1（***） BDUP2 group 3.4±0.5（***） 33±2.68（***） 27±1.06（***） 18.4±1.9（***） p-BDUP2 group 4.6±0.2（***） 56±1.54（***） 39±2.02（***） 22.9±2.7（*）

[0056] Note: Significant difference is compared with the model group.

[0057] ② The BDU2P strain improved the thymus index and spleen index of eczema model mice

[0058] Observation of experimental mice found that the mice had obvious swelling, erythema, edema, and allergic reactions such as papules on the ears, indicating that the modeling was successful.

[0059] Ear swelling is the average right ear thickness value, and the degree of ear swelling can reflect the severity of inflammation. During the experiment, DNCB induced eczema in mice, and the skin condition gradually worsened. The right ear of the model group mice was obviously swollen, with a swelling degree of 0.15 mm (experimental results are shown in Table 2). The ear swelling of the BDU2P live bacteria group mice was significantly improved, with a swelling degree of 0.05 mm. The inactivated bacteria group also alleviated the swelling inflammation of the mouse ears, but the effect was slightly lower than that of the live bacteria group (swelling degree of 0.08 mm), indicating that both the live and inactivated B. paraplastiferum BDUP2 can alleviate the inflammatory phenotype of eczema mice.

[0060] Table 2. Right ear thickness and swelling degree of mice

[0061] Group Right ear thickness (mm) Swelling degree (mm) Blank group 0.21±0.01 0.02±0.00 Model group 0.48±0.01 0.15±0.00 Dex group 0.22±0.01（***） 0.03±0.00（***） BDUP2 group 0.26±0.02（***） 0.05±0.01（***） p-BDUP2 group 0.34±0.01（***） 0.08±0.01（***）

[0062] Note: Significant difference is compared with the model group.

[0063] The results are shown in Table 3. After the experiment, the body weight of mice in each group had no significant difference, ranging from 29.14 to 30.44 g, indicating that eczema induced by DNCB did not affect the growth of mice. The influence of eczema on the thymus index and spleen index of each group was observed. Compared with the blank group, the thymus index (1.99 vs 3.76) and spleen index (4.18 vs 5.43) of the model group mice were significantly increased. After treatment with B. paraplastiferum (live bacteria / inactivated bacteria), the thymus index and spleen index of eczema mice were significantly decreased and basically returned to normal levels, and the influence of the inactivated bacteria group on the two indices was slightly weaker than that of the live bacteria. These results showed that eczema induced by DNCB could damage the immune organs of mice, and B. paraplastiferum BDUP2 could protect the thymus and spleen of eczema mice.

[0064] Table 3. Body weight, thymus and spleen index of mice

[0065] Group Initial body weight (g) Final body weight (g) Thymus index Spleen index Blank group 21.58±0.76 29.14±0.60 1.99±0.04 4.18±0.09 Model group 21.79±0.66 29.18±0.76 3.76±0.11 5.43±0.08 Dex group 21.32±0.78 (ns) 29.45±0.65 (ns) 2.18±0.07（***） 4.21±0.10（***） BDUP2 group 21.45±0.41 (ns) 30.18±0.44 (ns) 2.28±0.18（***） 4.36±0.09（***） p-BDUP2 group 21.34±0.36 (ns) 30.26±0.33 (ns) 2.50±0.11（***） 4.53±0.09（***）

[0066] Note: Significant difference is compared with the model group.

[0067] ③ BDUP2 strain reduces specific antibodies and immune cytokines in the serum of mice with eczema model

[0068] According to Figure 2 Compared with the blank group, the contents of total IgE and IgG1 in the serum of the eczema model group were significantly increased, indicating that the Th2 type inflammatory response of the eczema mice induced by DNCB was enhanced. Compared with the model group, the IgE content was significantly reduced to 7.44 μg / mL after treatment with BDUP2 live bacteria, and the IgG1 content was 530.97 μg / mL; the IgE content of the inactivated strain (p-BDUP) group was 10.11 μg / mL, and the IgG content was 1004.48 μg / mL. It was shown that Lactobacillus gasseri BDUP2 could reduce the abnormal secretion of IgE and IgG1 caused by inflammation and inhibit the increase of specific antibodies in the serum of mice.

[0069] As Figure 3 shown, in the experiment of exploring the effect of Lactobacillus paragasseri BDUP2 on relieving eczema in the eczema mouse model induced by DNCB, the detection and analysis of the levels of key inflammatory factors in the serum could directly reflect the intervention effect of each experimental group. Compared with the blank group, the levels of pro-inflammatory factors IL-4, IL-13, IL-31 and TNF-α in the serum of the model group mice were significantly increased, while the levels of anti-inflammatory factors IL-10 and IFN-γ were decreased, highlighting the immune imbalance of the body in the state of eczema.

[0070] Dex positive group as a control showed certain effect in regulating serum inflammatory factors. Among the intervention groups, the BDUP2 active bacteria group showed good regulation ability, which could significantly reduce the levels of IL-4, IL-13, IL-31 and TNF-α, and increase the levels of IL-10 and IFN-γ. Although the p-BDUP2 inactivated bacteria group could regulate the levels of inflammatory factors to some extent, the effect was significantly weaker than that of the corresponding live bacteria intervention group. This fully showed that BDUP2 active bacteria had significant effects in regulating serum inflammatory factors, improving immune imbalance and relieving eczema.

[0071] ④ BDUP2 strain reduces the itch-related factors in the serum of mice with eczema model

[0072] Figure 4As shown in the experiment of the mouse model of eczema induced by DNCB, compared with the blank group, the levels of the itching-related factors Substance P (SP), calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) in the serum of the mice in the model group increased sharply, highlighting the strong neurogenic inflammatory response caused by eczema. The levels of the above factors in the Dex positive control mice decreased significantly compared with the model group, indicating that Dex can effectively weaken the signal transmission of itching. The treatment of the BDUP2 active bacteria group can effectively reduce the levels of SP, CGRP and NGF, showing the advantage of BDUP2 active bacteria in relieving itching-related factors. The p-BDUP2 inactivated bacteria group can also up-regulate the levels of the factors, and the effect is slightly weaker than that of the active bacteria group.

[0073] In summary, the treatment of BDUP2 bacteria can regulate itching-related factors, and the effect of BDUP active bacteria is better than that of inactivated bacteria, and is close to that of the positive reference Dex, indicating that the BDUP strain of the application can relieve itching by reducing the levels of related neuropeptides.

[0074] ⑤ BDUP2 strain relieves skin inflammation-related oxidative damage in mice

[0075] According to Figure 5 Compared with the normal group, the MDA content in the skin tissue of the mice in the model group increased significantly, and the SOD activity decreased significantly. After intervention, the MDA content in the Dex group and the BDUP2 active bacteria group was significantly lower than that in the model group, and the SOD activity was significantly higher than that in the model group. The effect of the BDUP2 inactivated bacteria group was worse than that of the BDUP2 active bacteria group, but still significantly different from that of the model group. Among them, the MDA of the BDUP2 active bacteria group was 1.86 nmol / mg protein, and the SOD was 41.44 U / mg protein; the MDA of the BDUP2 inactivated bacteria group was 2.89 nmol / mg protein, and the SOD was 31.22 U / mg protein. The results show that the antioxidant stress effect of the BDUP2 active bacteria group is better than that of the p-BDUP2 inactivated bacteria group, and is slightly weaker than that of the Dex group.

[0076] ⑥ BDUP2 strain relieves mouse eczema-like discomfort by down-regulating the itching neural pathway

[0077] As Figure 6 shown in the DNCB-induced eczema mouse model, RT-qPCR detection showed that the relative expression of mRNA of Nppb, MrgprA3, IL-31 and TRPV1 in the skin tissue of the blank group was at a low basic level (1.0 for the blank group); the relative expression of mRNA of the above genes in the model group increased significantly, suggesting that these inflammation and itching-related genes were abnormally activated under the condition of eczema.

[0078] The Dex positive group can effectively down-regulate the mRNA expression of the four genes, reflecting the inhibitory effect on the molecular pathway related to eczema. The BDUP2 active bacteria group shows the best down-regulation effect on the mRNA expression of the above genes, while the p-BDUP2 inactivated bacteria group is weaker than the active bacteria group. Therefore, the BDUP2 active bacteria can relieve eczema by down-regulating the mRNA expression of Nppb, MrgprA3, IL-31 and TRPV1 in the skin tissue of the eczema mice, and the active state is an important prerequisite for the function.

[0079] In summary, the B. paraplastiferum BDUP2 of the present application can regulate the itch neural pathway, reduce the production of itch factors and neuropeptides, and thus improve itch.

[0080] The above examples show that the B. paraplastiferum BDUP2 of the present application can effectively improve the skin barrier function, relieve the itch behavior and eczema-like inflammatory response in the DNCB-induced mouse eczema model. The working mechanism is related to the inhibition of Th2-type immune response, support of immune balance, and regulation of the itch perception neural pathway, regulation of itch factors and neuropeptides. The above effects show that the B. paraplastiferum BDUP2 has application value in food, health products or cosmetics, and can be used for the development of products for improving skin condition, relieving eczema-like discomfort and supporting skin health, providing consumers with a new safe and effective choice for skin management.

Claims

1. Lactobacillus paragasseri BDUP2, having the accession number CGMCC No. 35759.

2. Use of live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1 in the manufacture of a product for improving skin health or supporting skin barrier function.

3. Use of live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1 in the manufacture of a product for relieving eczema-like discomfort.

4. The use according to claim 2, wherein, The product is for improving skin health or supporting skin barrier function, including relieving skin redness, dryness, scaling, reducing transepidermal water loss.

5. The use according to claim 3, wherein, The product is for relieving conditions associated with eczema-like discomfort including skin swelling, redness, dryness, scaling, crusting, itching, inflammatory response or skin oxidative damage.

6. Use of live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1 in the manufacture of a product for modulating pruritogenic factors or pruritogenic peptides levels.

7. Use of live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1 in the manufacture of a product for relieving skin oxidative damage, or enhancing skin antioxidant defense.

8. A product comprising an effective amount of live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1.

9. The product of claim 8, which is a food, a nutraceutical or a cosmetic.

10. A method of product preparation, the method comprising: The live, dead, metabolites, supernatant, inoculum or composition of Lactobacillus paragasseri BDUP2 of claim 1 is added to a product matrix to obtain the product.

Images